December 19, 2018

Pisano Presents Benefits of TMIST Participation at ACR RBMA Practice Leaders Forum

ACR Chief Research Officer, Etta Pisano, MD

Tomosynthesis Mammographic Imaging Screening Trial (TMIST) principal investigator Etta Pisano, MD, will show 2019 ACR-RBMA Practice Leaders Forum attendees how taking part in the landmark trial can benefit their practices and advance patient care. Pisano will speak during the Forum plenary session Jan. 12 at 1pm Central Time at the Hyatt Regency, Houston.

TMIST is the first large randomized, controlled trial (RCT) that would identify women in which digital breast tomosynthesis (DBT) may outpace (2D) digital mammography at reducing advanced breast cancer development. Decision makers rarely update clinical or payment policy without an RCT in the evidence base.

Nearly 50 sites are already open and accruing patients, but the trial is looking to add 80 more sites throughout North America. TMIST is enrolling 165,000 healthy women, ages 45 to 74, who are already planning to get routine mammograms.

The cost of screening mammography or tomosynthesis is reimbursed through the usual mechanisms of private insurance, Medicare or Medicaid.

On top of that, the study pays facilities $500 for the submission of data on each recruited subject through NCTN group affiliation and $150 for data on each follow-up mammogram required under the study protocol.

TMIST also has a special fund that pays facilities $138.17 per study for uninsured subjects, who qualify for charity care at your institution, to receive screening mammography.

TMIST will create the world’s largest curated dataset of breast cancer screening clinical data, images and bio-specimens to inform future, more tailored, screening policy.

Patients will be asked to voluntarily submit blood samples and swabs of buccal cells from the inside of the mouth.

Researchers will analyze study-related biopsy tissue to learn more about the biology of screening-detected cancers.

The study will provide additional payments to sites for submission of biopsy samples and blood and buccal smear samples.

Previous, smaller prospective studies have shown that breast tomosynthesis reduces the number of callbacks and false positive exams, while finding more overall cancers — compared to standard mammography. This previous research helped prompt federal funding of TMIST.

See more information on TMIST in this recent Advocacy in Action Q+A with Dr. Pisano.

To receive information on becoming a TMIST study site, contact Jessica Howell, TMIST Project Manager, at

For more TMIST information and a list of participating centers, see:

To find TMIST information on social media: #TMIST4BC.